Phibro Animal Health Corporation (PAHC) Guidance & Earnings Results

On 2026-08-26 Phibro Animal Health Corporation reaffirmed guidance: "FY27 net sales $1.55-1.60B; FY27 adjusted EBITDA $258-268M; FY27 adjusted net income $140-147M; FY27 adjusted diluted EPS…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

PAHCPhibro Animal Health CorporationFollow PAHC — free

Drug Manufacturers - Specialty & Generic · Healthcare

—

Price chart with a free account

Market cap: 1.6B
P/E TTM: 15.9
Dividend yield: 1.2%
52-week: —
Next earnings: 11 Nov, in 18 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
26 Aug 26	Reaffirmed	FY27 net sales $1.55-1.60B; FY27 adjusted EBITDA $258-268M; FY27 adjusted net income $140-147M; FY27 adjusted diluted EPS $3.41-3.59 · full year
6 May 26	Raised	FY2026 net sales guidance $1.46B-$1.50B (midpoint raised); adjusted EBITDA $247M-$255M (midpoint raised) · full year
4 Feb 26	Raised	Net sales $1.45B-$1.50B; Adjusted EBITDA $245M-$255M · full year
5 Nov 25	Raised	FY2026 Adjusted EBITDA guidance raised to $230-240M from prior; Net sales guidance maintained at $1.43-1.48B · full year
27 Aug 25	Raised	FY2026 net sales $1.43B-$1.48B; adjusted EBITDA $225M-$235M · full year

Phibro Animal Health Corporation — questions

What guidance did Phibro Animal Health Corporation give?: On 2026-08-26: "FY27 net sales $1.55-1.60B; FY27 adjusted EBITDA $258-268M; FY27 adjusted net income $140-147M; FY27 adjusted diluted EPS $3.41-3.59"
When does Phibro Animal Health Corporation report earnings?: Phibro Animal Health Corporation's next earnings report is expected on 2026-11-11.

Every figure on this page comes from Phibro Animal Health Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.